We are live on ! Find out more

Mirum Pharmaceuticals

MIRM

Market cap $5.61B

86.39 USD

+0.58

0.68%

At close Updated Oct 29, 4:00 PM EDT

1 day

0.68%

5 days

4.85%

1 month

-1.31%

3 months

-19.69%

6 months

-8.29%

Year to date

10.66%

1 year

22.61%

5 years

444.02%

10 years

553.97%

About: Mirum Pharmaceuticals Inc. is a biopharmaceutical company focused on developing and commercializing therapies for rare and orphan diseases. Its main product, Livmarli (maralixibat), is an orally administered IBAT inhibitor approved to treat cholestatic pruritus in patients with Alagille syndrome. The company is also developing treatments such as maralixibat for PFIC and ALGS, and volixibat for adult cholestatic liver diseases. Mirum currently has three approved medicines: Livmarli, Cholbam, and Ctexli.

Employees: 433

Healthcare Biotechnology

News

Positive

Neutral

Negative

Sentiment 3-Months

Positive 35.3%

Neutral 61.8%

Negative 2.9%

Mirum Pharmaceuticals to Announce Third Quarter 2026 Financial Results and Host Conference Call on November 3, 2026

FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals to Announce Third Quarter 2026 Financial Results and Host Conference Call on November 3, 2026.

Mirum Pharmaceuticals to Announce Third Quarter 2026 Financial Results and Host Conference Call on November 3, 2026

Zacks Investment Research

Mirum Pharmaceuticals, Inc. (MIRM) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release

Mirum Pharmaceuticals (MIRM) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Mirum Pharmaceuticals, Inc. (MIRM) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release

Mirum Pharmaceuticals Announces Positive Results from Cohort 2 of the Pivotal PROGRESS Study of ATEBRIOZ™ (zilurgisertib) in Pediatric Patients Aged 6 to

FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Announces Positive Results from Cohort 2 of the Pivotal PROGRESS Study of ATEBRIOZ™ (zilurgisertib) in Patients Aged 6 to

Mirum Pharmaceuticals Announces Positive Results from Cohort 2 of the Pivotal PROGRESS Study of ATEBRIOZ™ (zilurgisertib) in Pediatric Patients Aged 6 to

Mirum Pharmaceuticals to Participate in Upcoming Investor Conferences

FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals to Participate in Upcoming Investor Conferences.

Mirum Pharmaceuticals to Participate in Upcoming Investor Conferences

Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4).

Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Zacks Investment Research

Mirum's Livmarli Meets Phase III Goal in Ultra-Rare Liver Diseases

MIRM's Livmarli meets the phase III EXPAND study goal, improving cholestatic pruritus and reducing serum bile acids, with an FDA filing planned for 2027.

Mirum's Livmarli Meets Phase III Goal in Ultra-Rare Liver Diseases

Mirum Pharmaceuticals, Inc. (MIRM) Discusses Phase 3 EXPAND Study Results for Maralixibat in Cholestatic Pruritus Including Biliary Atresia Transcript

Mirum Pharmaceuticals, Inc. (MIRM) Discusses Phase 3 EXPAND Study Results for Maralixibat in Cholestatic Pruritus Including Biliary Atresia Transcript

Mirum Pharmaceuticals, Inc. (MIRM) Discusses Phase 3 EXPAND Study Results for Maralixibat in Cholestatic Pruritus Including Biliary Atresia Transcript

Mirum Pharmaceuticals' LIVMARLI Study Hits Key Endpoints in Rare Liver Diseases

Mirum Pharmaceuticals NASDAQ: MIRM said its Phase III EXPAND study of LIVMARLI, or maralixibat, met its primary endpoint and all prespecified secondary endpoints in pediatric patients with cholestatic pruritus associated with ultra-rare cholestatic liver diseases.

Mirum Pharmaceuticals' LIVMARLI Study Hits Key Endpoints in Rare Liver Diseases

Mirum Pharmaceuticals Announces Primary Endpoint Met in Phase 3 EXPAND Study of LIVMARLI® (maralixibat) in Ultra-Rare Cholestatic Liver Diseases

FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals Announces Primary Endpoint Met in Phase 3 EXPAND Study of LIVMARLI® (maralixibat) in Ultra-Rare Cholestatic Liver Diseases.

Mirum Pharmaceuticals Announces Primary Endpoint Met in Phase 3 EXPAND Study of LIVMARLI® (maralixibat) in Ultra-Rare Cholestatic Liver Diseases

Mirum Pharmaceuticals to Host Investor Call to Share Topline Results from the Phase 3 EXPAND Study of LIVMARLI® (maralixibat) in Ultra-Rare Cholestatic Liver Diseases

FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum to Host Call to Share Topline Results from the Phase 3 EXPAND Study of LIVMARLI® (maralixibat) in Ultra-Rare Cholestatic Liver Diseases.

Mirum Pharmaceuticals to Host Investor Call to Share Topline Results from the Phase 3 EXPAND Study of LIVMARLI® (maralixibat) in Ultra-Rare Cholestatic Liver Diseases

See News Rankings

Price charts implemented using Lightweight Charts™